Antimicrobial susceptibility of clinical isolates of anaerobic bacteria in Ontario, 2010-2011

Anaerobe

Volumn 28, Issue , 2014, Pages 120-125

  Marchand Austin, Alex ^a,b   Rawte, Prasad ^a   Toye, Baldwin ^c   Jamieson, Frances B ^a,b   Farrell, David J ^a,b   Patel, Samir N ^a,b  

^a PUBLIC HEALTH ONTARIO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Anaerobes; B.fragilis; Susceptibility data

Indexed keywords

BETA LACTAM; CEFOXITIN; CLINDAMYCIN; MEROPENEM; METRONIDAZOLE; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT;

ACTINOBACTERIA; ACTINOMYCES; ANAEROBIC BACTERIUM; ANAEROCOCCUS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM DETECTION; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATION; BACTEROIDES FRAGILIS; BIFIDOBACTERIUM; CANADA; CLOSTRIDIUM; CLOSTRIDIUM PERFRINGENS; COLLINSELLA; EGGERTHELLA; EUBACTERIUM; FINEGOLDIA MAGNA; FUSOBACTERIUM; FUSOBACTERIUM NUCLEATUM; GRAM POSITIVE BACTERIUM; IN VITRO STUDY; LACTOBACILLUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PARVIMONAS MICRA; PREVOTELLA; PRIORITY JOURNAL; PROPIONIBACTERIUM; TRACHEOBRONCHIAL TOILET; VEILLONELLA; ADOLESCENT; ADULT; AGED; BACTERIAL INFECTIONS; CHILD; DRUG EFFECTS; FEMALE; HUMAN; INFANT; ISOLATION AND PURIFICATION; MALE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; NEWBORN; PRESCHOOL CHILD; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTERIA, ANAEROBIC; BACTERIAL INFECTIONS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; ONTARIO; YOUNG ADULT;

EID: 84902975223     PISSN: 10759964     EISSN: 10958274     Source Type: Journal    
DOI: 10.1016/j.anaerobe.2014.05.015     Document Type: Article

References (24)

1. Finegold S.M., George W.L. Anaerobic infections in humans 1989, Academic Press, San Diego.
2. Aldridge K.E., Ashcraft D., Cambre L., Pierson C.L., Jenkins S.G., Rosenblatt J.E. Multicenter survey of the changing invitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group, Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus species. Antimicrob Agents Chemother 2001, 45:1238-1243.
3. Labbe A.C., Bourgault A.M., Vincelette J., Turgeon P.L., Lamothe F. Trends in antimicrobial resistance among clinical isolates of the Bacteroides fragilis group from 1992 to 1997 in Montreal, Canada. Antimicrob Agents Chemother 1999, 43:2517-2519.
4. Milatovic D., Schmitz F.J., Brisse S., Verhoef J., Fluit A.C. Invitro activities of sitafloxacin (DU-6859a) and six other fluoroquinolones against 8,796 clinical bacterial isolates. Antimicrob Agents Chemother 2000, 44:1102-1107.
5. Goldstein E., Citron D.M. Resistance trends in antimicrobial susceptibility of anaerobic bacteria, part 1. Clin Microbiol Newslett 2011, 33:1-8.
6. Snydman D.R., Jacobus N.V., McDermott L.A., Golan Y., Hecht D.W., Goldstein E.J., et al. Lessons learned from the anaerobe survey: historical perspective and review of the most recent data (2005-2007). Clin Infect Dis 2010, 50(Suppl.1):S26-S33.
7. Nguyen M.H., Yu V.L., Morris A.J., McDermott L., Wagener M.W., Harrell L., et al. Antimicrobial resistance and clinical outcome of Bacteroides bacteremia: findings of a multicenter prospective observational trial. Clin Infect Dis 2000, 30:870-876.
8. Koeth L.M., Good C.E., Appelbaum P.C., Goldstein E.J., Rodloff A.C., Claros M., et al. Surveillance of susceptibility patterns in 1297 European and US anaerobic and capnophilic isolates to co-amoxiclav and five other antimicrobial agents. JAntimicrob Chemother 2004, 53:1039-1044.
9. Finegold S.M. Perspective on susceptibility testing of anaerobic bacteria. Clin Infect Dis 1997, 25(Suppl.2):S251-S253.
10. Liu C.Y., Huang Y.T., Liao C.H., Yen L.C., Lin H.Y., Hsueh P.R. Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. Antimicrob Agents Chemother 2008, 52:3161-3168.
11. Karlowsky J.A., Walkty A.J., Adam H.J., Baxter M.R., Hoban D.J., Zhanel G.G. Prevalence of antimicrobial resistance among clinical isolates of Bacteroides fragilis group in Canada in 2010-2011: CANWARD surveillance study. Antimicrob Agents Chemother 2012, 56:1247-1252.
12. Knox C.M., Cevellos V., Dean D. 16S ribosomal DNA typing for identification of pathogens in patients with bacterial keratitis. JClin Microbiol 1998, 36:3492-3496.
13. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing; twenty-third informational supplement M100-S23 2013, Clinical and Laboratory Standards Institute, Wayne, Pennsylvania.
14. Wexler H.M. Bacteroides: the good, the bad, and the nitty-gritty. Clin Microbiol Rev 2007, 20:593-621.
15. Eitel Z., Soki J., Urban E., Nagy E. ESCMID study group on anaerobic infection. The prevalence of antibiotic resistance genes in Bacteroides fragilis group strains isolated in different European countries. Anaerobe 2013, 21:43-49.
16. Nagy E., Urban E., Nord C.E. ESCMID study group on antimicrobial resistance in anaerobic bacteria. Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe: 20 years of experience. Clin Microbiol Infect 2011, 17:371-379.
17. Snydman D.R., Jacobus N.V., McDermott L.A., Golan Y., Goldstein E.J., Harrell L., et al. Update on resistance of Bacteroides fragilis group and related species with special attention to carbapenems 2006-2009. Anaerobe 2011, 17:147-151.
18. Brook I., Frazier E.H. Infections caused by Propionibacterium species. Rev Infect Dis 1991, 13:819-822.
19. Huynh T.T., Walling A.D., Miller M.A., Leung T.K., Leclerc Y., Dragtakis L. Propionibacterium acnes endocarditis. Can J Cardiol 1995, 11:785-787.
20. Jakab E., Zbinden R., Gubler J., Ruef C., von Graevenitz A., Krause M. Severe infections caused by Propionibacterium acnes: an underestimated pathogen in late postoperative infections. Yale J Biol Med 1996, 69:477-482.
21. Perry A., Lambert P. Propionibacterium acnes: infection beyond the skin. Expert Rev. Anti Infect Ther 2011, 9:1149-1156.
22. Park H.J., Na S., Park S.Y., Moon S.M., Cho O.H., Park K.H., et al. Clinical significance of Propionibacterium acnes recovered from blood cultures: analysis of 524 episodes. JClin Microbiol 2011, 49:1598-1601.
23. Tansuphasiri U., Matra W., Sangsuk L. Antimicrobial resistance among Clostridium perfringens isolated from various sources in Thailand. Southeast Asian J Trop Med Public Health 2005, 36:954-961.
24. Teng L.J., Hsueh P.R., Tsai J.C., Liaw S.J., Ho S.W., Luh K.T. High incidence of cefoxitin and clindamycin resistance among anaerobes in Taiwan. Antimicrob Agents Chemother 2002, 46:2908-2913.